Federated Hermes Inc. lifted its stake in Doximity, Inc. (NASDAQ:DOCS - Free Report) by 8.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 256,549 shares of the company's stock after buying an additional 19,861 shares during the period. Federated Hermes Inc. owned approximately 0.14% of Doximity worth $13,697,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds also recently made changes to their positions in DOCS. Integrated Wealth Concepts LLC purchased a new stake in shares of Doximity in the third quarter worth approximately $308,000. Morse Asset Management Inc purchased a new stake in shares of Doximity in the third quarter worth about $46,000. State Street Corp grew its position in shares of Doximity by 2.5% during the 3rd quarter. State Street Corp now owns 3,693,982 shares of the company's stock valued at $160,947,000 after purchasing an additional 88,922 shares in the last quarter. Orion Portfolio Solutions LLC bought a new position in Doximity in the 3rd quarter worth about $260,000. Finally, Barclays PLC raised its stake in Doximity by 60.5% in the third quarter. Barclays PLC now owns 53,401 shares of the company's stock valued at $2,327,000 after purchasing an additional 20,125 shares in the last quarter. Institutional investors and hedge funds own 87.19% of the company's stock.
Insider Transactions at Doximity
In related news, Director Timothy S. Cabral sold 20,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $57.62, for a total value of $1,152,400.00. Following the transaction, the director now directly owns 6,360 shares of the company's stock, valued at approximately $366,463.20. This trade represents a 75.87 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 37.40% of the company's stock.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on DOCS shares. Truist Financial cut their target price on Doximity from $65.00 to $58.00 and set a "hold" rating on the stock in a research note on Thursday, April 10th. KeyCorp reduced their price target on Doximity from $70.00 to $65.00 and set an "overweight" rating for the company in a report on Wednesday, January 8th. Wells Fargo & Company reiterated an "equal weight" rating on shares of Doximity in a research note on Friday, February 7th. Raymond James reiterated an "outperform" rating and issued a $83.00 price target (up from $65.00) on shares of Doximity in a research note on Friday, February 7th. Finally, Stephens assumed coverage on Doximity in a research report on Friday, December 20th. They set an "equal weight" rating and a $55.00 target price on the stock. Eleven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Doximity has an average rating of "Moderate Buy" and a consensus price target of $64.72.
View Our Latest Analysis on Doximity
Doximity Price Performance
NASDAQ:DOCS traded up $0.67 during trading hours on Tuesday, reaching $53.27. 528,112 shares of the company traded hands, compared to its average volume of 1,974,595. The firm's 50-day moving average is $64.63 and its 200-day moving average is $55.65. Doximity, Inc. has a 1-year low of $22.96 and a 1-year high of $85.21. The stock has a market cap of $9.94 billion, a P/E ratio of 53.25, a P/E/G ratio of 4.10 and a beta of 1.41.
Doximity Profile
(
Free Report)
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
Featured Articles

Before you consider Doximity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.
While Doximity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.